Aptevo Therapeutics Inc.
APVODrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TRU-016 and bendamustine | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aptevo Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Aptevo Therapeutics Inc.'s (APVO) pipeline across Phase 2. Its lead program is TRU-016 and bendamustine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aptevo Therapeutics Inc.'s next FDA catalyst?→
Aptevo Therapeutics Inc.'s (APVO) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APVO biotech catalysts?→
Add APVO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aptevo Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.